Spyre Therapeutics, Inc. (SYRE)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 53/100 (HIGH), 16.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 14.99% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below Market
- Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
- Spyre Therapeutics stock falls on public offering launch
- Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
- Spyre Therapeutics Announces Grants of Inducement Awards
- Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests
- Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?
- Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Spyre Therapeutics, Inc..
Full SYRE Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.